Von Willebrand disease


Authors: P. Smejkal;  M. Matýšková;  M. Penka
Authors‘ workplace: Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.
Published in: Vnitř Lék 2008; 54(3): 257-264
Category: Review

Overview

Von Willebrand disease is the most spread hereditary bleeding disorder with prevalence up to the 1 % in the population. Haemorrhagic symptoms are various intensity, mostly not severe. A large part of affected patients do not come to see a doctor. However these patients are potentially endangered by a serious haemorrhage after a trauma, surgery or during another illness. The estimated number of patients with von Willebrand disease is 1,500-3,500 per 1,000,000 of population; the number of persons with symptomatic von Willebrand disease was estimated to be at least 100 per million. This disease deserves attention not only by haematologists but other physicians too. In our communication we present short overview about von Willebrand disease: there are briefly described pathophysiology, classification, diagnosis and treatment of this illness.

Key words:
von Willebrand factor - von Willebrand disease - classification - diagnosis - treatment


Sources

1. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.

2. Ginsburg D, Bowie EJW. Molecular genetics of von Willebrand disease. Blood 1992; 79: 2507-2519.

3. Holmberg L, Nilsson M. Von Willebrand’s disease. Eur J Haematol 1992; 48: 127-141.

4. Miller JL. Von Willebrand disease. Hematom/Oncol Clin North Am 1990; 4: 107-127.

5. Schneppenheim R. Hämostaseologishe und molekulare Diagnostik des Von-Willebrand-Syndroms. Hämostaseologie 1994; 14: 159-169.

6. Murray EW. Von Willebrand disease: Pathogenesis, classification and management. Transf Med Rev 1996; 10: 93-110.

7. Lyons SE, Ginsburg D. Molecular and cellular biology of von Willebrand factor. Trends Cardiovasc Med 1994; 4: 34-39.

8. Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-174.

9. Eikenboom JC, Reitsma PH, Briët E. The inheritance and molecular genetics of von Willebranďs disease. Haemophilia 1995; 1: 77-90.

10. <http://www.med.unc.edu/isth/SSC/99minutes/toc99.htm>

11. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-525.

12. James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 145-154.

13. Goodeve A, Einkenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnose with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1 VWD). Blood 2007; 109: 112-121.

14. Lee CA, Berntorp EE, Hoots WK. Textbook of Hemophilia. 1. ed. Oxford: Blackwell Publishing 2005.

15. Zimmerman TS, Ruggeri ZM. Von Willebranďs disease. Clin Haematol 1983; 12: 175-199.

16. Budde U, Drewke E, Mainusch K et al. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002; 28: 173-190.

17. Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999; 82: 585-591.

18. Veyradier A, Jenkins ChSP, Fressinaud E et al. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84: 175-182.

19. Eikenboom JC, Van der Meer FJM, Briet E. Acquired von Willebranďs disease due to excessive fibrinolysis. Br J Haematol 1992; 81: 618-620.

20. Jakway JL. Acquired von Willebrand s disease. Hematom/Oncol Clin North Am 1992; 6: 1409-1420.

21. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebranďs disease the link? Lancet 1992; 340: 35-37.

22. Kreuz W, Linde R, Funk M et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 1992; 33: 178-184.

23. Federici AB, Castaman G, Mannucci PM et al. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-621.

24. Federici AB, Mannucci PM. Diagnosis and management of von Willebrand disease. Haemophilia 1999; 5(Suppl 2): 28-37.

25. Dean JA, Blanchette VS, Carcao MD et al. von Willebrand disease in a pediatric based population - Comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000; 84: 401-89.

26. Ingerslev J, Gürsel T. Diagnosis of von Willebrand disease. Haemophilia 1999; 5(Suppl 2): 50-56.

27. Favaloro EJ, Smith J, Petinos P et al. Laboratory testing for von Willebrand’s disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in haematology haemostasis scientific advisory panel. Thromb Haemost 1999; 82: 1276-1282.

28. Vanhoorelbeke K, Cauwenberghs N, Vauterin S et al. A Reliable and Reproducible ELISA Metod to Measure Ristocetin Cofactor Aktivity of von Willebrand Factor. Throbm Haemost 2000; 83:107-113.

29. Vanhoorelbeke K, Pareyn I, Schlammadinger A et al. Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA. Throbm Haemost 2005; 93: 165-171.

30. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand’s disease. Blood Reviews 1999; 13: 185-204.

31. Favaloro EJ Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Am J Clin Pathol 2000; 114: 608-618.

32. Riddell AF, Jenkins PV, Nitu-Whalley IC et al. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haemat 2002; 116: 187-192.

33. Turek P, Sikorová J, Vorlová Z. Stanovení von Willebrandova faktoru. Vnitř Lék 1984; 30: 550-556.

34. Habart D. Von Willebrandova choroba typu 2N (Normandy). Vnitř Lék 2003; 49: 253-255.

35. Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of vWD type 1. J Thromb Haemost 2005; 3: 775-777.

36. Kadir RA, Economides DL, Sabin CA et al. Variations in coagulation factor in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82: 1456-1461.

37. Levy G, Ginsburg D. Getting at the variable expressivity of von Willebrand disease. Thromb Haemost 2001; 86: 144-148.

38. Mannucci PM Desmopressin (DDAVP) in the treatment of bleeding disorders: the First 20 Years. Blood 1997; 90: 2515-2521.

39. Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost 2001; 86: 149-153.

40. Mazurier C, Guacher Ch, Jorieux S et al. Biological effect of desmopressin in eight patients with type 2N (“Normandy”) von Willebrand disease. Br J Haematol 1994; 88: 849-854.

41. Pasi KJ, Collins PW, Keeling DM et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004; 10: 218-231.

42. Chang AC, Rick ME, Pierce LR et al. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4(Suppl 3): 1-6.

43. Berntorp E. Von Willebrand factor containing factor VIII concentrates. Haemophilia 1999; 5(Suppl 2): 60-63.

44. Federici AB, Castaman G, Thompson A et al. Von Willebrand’s disease: clinical management. Haemophilia 2006; 12(Suppl 3): 152-158.

45. Goudemand J, Scharrer I, Berntorp E et al. Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005; 3: 2219-2227.

46. Berntorp E. Plasma product treatment in various types of von Willebrand’s disease. Haemostasis 1994; 24: 289-297.

47. Ramsahoye BH, Davies SV, Dasani H et al. Obstetric management in von Willebrand’s disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 140-144.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account